Janus kinase inhibitors for hospitalized patients with COVID-19: a meta-analysis of randomized controlled trials.
Expert Rev Anti Infect Ther
; 20(5): 773-779, 2022 05.
Article
in English
| MEDLINE | ID: covidwho-1500923
ABSTRACT
BACKGROUND:
This meta-analysis of randomized controlled trials (RCTs) investigated the usefulness of Janus kinase (JAK) inhibitors among hospitalized patients with COVID-19.METHODS:
PubMed, Web of Science, the Cochrane Library, and Ovid MEDLINE were searched for RCTs published before 7 September 2021. Only RCTs that compared the clinical efficacy and safety of JAK inhibitors with other alternative treatments or placebos in the treatment of hospitalized patients with COVID-19 were included.RESULTS:
Overall, patients receiving JAK inhibitors exhibited a lower 28-day mortality rate than the control group (risk ratio [RR], 0.60; 95% CI, 0.47-0.77; I2 = 0%). Compared with the control group, the study group also had a lower 14-day mortality rate (RR, 0.60; 95% CI, 0.42-0.85; I2 = 0%), a higher rate of clinical improvement (RR, 1.05; 95% CI, 1.02-1.09; I2 = 0%), and less need of mechanical ventilation or extracorporeal membrane oxygenation (RR, 0.64; 95% CI, 0.50-0.84; I2 = 0%). Finally, JAK inhibitor use was associated with a similar risk of adverse events and infections as that observed in the control group.CONCLUSIONS:
JAK inhibitors can help reduce mortality and improve clinical outcomes among hospitalized patients with COVID-19. Additionally, JAK inhibitors can be used safely in this clinical entity.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Janus Kinase Inhibitors
/
COVID-19 Drug Treatment
Type of study:
Experimental Studies
/
Prognostic study
/
Randomized controlled trials
/
Reviews
Limits:
Humans
Language:
English
Journal:
Expert Rev Anti Infect Ther
Journal subject:
Communicable Diseases
Year:
2022
Document Type:
Article
Affiliation country:
14787210.2022.2004120
Similar
MEDLINE
...
LILACS
LIS